Contents
Participation in medical research should be accessible to everyone. We can bridge the gap between health volunteers, organizations, and groundbreaking clinical research, right here in Connecticut.
Together, we can push boundaries, challenge the status quo, and drive progress where it matters most. Your participation has the power to transform lives.
Clinical Trials For Disease Areas in Connecticut
Connecticut is a hotspot for medical innovation. With renowned institutions, like Grove Hill Clinical Research, experts are leading the way in various fields. Our state excels in the study of a wide range of diseases.
Clinical research trials in Connecticut are committed to pioneering investigations on cancer research, neurological disorders, mental health, chronic disease treatment, microbiology, and more. These research strengths make it a key player in the field of medicine.
Recently, Connecticut experts explained that another experimental drug for Alzheimer’s can slow a patient’s memory decline by roughly 4 to 7 months. The drug donanemab is waiting for FDA approval. If cleared, it could be a promising treatment for the disease.
Here is a list of active and future trials that could offer valuable results.
VItamin C in Thermal injuRY: The VICToRY Trial
Recruiting
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Bridgeport Hospital, Bridgeport, Connecticut
Bridgeport Hospital, Bridgeport, Connecticut
Conditions: Shock, Thermal Burn
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport, Connecticut +15 locations
Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport, Connecticut
Danbury Hospital, Danbury, Connecticut
Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut
Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut
Hartford Hospital, Hartford, Connecticut
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Midstate Medical Center, Meriden, Connecticut
The Hospital of Central Connecticut, New Britain, Connecticut
Yale University, New Haven, Connecticut
Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut
Norwalk Hospital, Norwalk, Connecticut
Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut
Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut
Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut
Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Bridgeport Hospital, Bridgeport, Connecticut +1 locations
Bridgeport Hospital, Bridgeport, Connecticut
Yale School of Medicine, New Haven, Connecticut
Conditions: NASH - Nonalcoholic Steatohepatitis
HEAL-IST IDE Trial
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Saint Vincent's Medical Center, Bridgeport, Connecticut
Saint Vincent's Medical Center, Bridgeport, Connecticut
Conditions: Inappropriate Sinus Tachycardia
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease. Read Less
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
08/21/2025
Locations: Greater Hartford Nephrology, Bloomfield, Connecticut +2 locations
Greater Hartford Nephrology, Bloomfield, Connecticut
Nephrology & Hypertension Associates, PC, Middlebury, Connecticut
Yale University - Yale Nephrology Clinical Research Clinic, New Haven, Connecticut
Conditions: Proteinuric Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: 84000176 - Greater Hartford Nephrology, LLC, Bloomfield, Connecticut +1 locations
84000176 - Greater Hartford Nephrology, LLC, Bloomfield, Connecticut
84000173 - Nephrology and Hypertension Associates PC, Middlebury, Connecticut
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Hartford HealthCare - Avon, Avon, Connecticut +4 locations
Hartford HealthCare - Avon, Avon, Connecticut
Hartford Hospital, Hartford, Connecticut
Hartford HealthCare - Manchester, Manchester, Connecticut
Midstate Medical Center, Meriden, Connecticut
The Hospital of Central Connecticut, New Britain, Connecticut
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients). Read Less
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
08/01/2025
Locations: Hartford HealthCare - Avon, Avon, Connecticut +21 locations
Hartford HealthCare - Avon, Avon, Connecticut
Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport, Connecticut
Danbury Hospital, Danbury, Connecticut
Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut
Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut
Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut
Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut
Hartford Hospital, Hartford, Connecticut
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Hartford HealthCare - Manchester, Manchester, Connecticut
Midstate Medical Center, Meriden, Connecticut
The Hospital of Central Connecticut, New Britain, Connecticut
Yale University, New Haven, Connecticut
Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut
Norwalk Hospital, Norwalk, Connecticut
Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut
Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut
Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut
Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut
Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut
Conditions: Breast Cancer
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
Recruiting
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center, Bridgeport, Connecticut +5 locations
Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center, Bridgeport, Connecticut
Griffin Hospital, Derby, Connecticut
Yale New Haven Health Greenwich Hospital, Greenwich, Connecticut
Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):, New Haven, Connecticut
Saint Raphael's Radiology and Biomedical Imaging, Basement Location., New Haven, Connecticut
Yale New Haven Health Lawrence & Memorial Hospital, New London, Connecticut
Conditions: Prostate Cancer
Breathwork Intervention for Posttraumatic Stress
Recruiting
The goal of this single-site, single-arm pilot study is to examine the impact of breathwork training for posttraumatic stress symptoms in an adult veteran population. Participants will complete a single, in-person breathwork session (2 hours) led by a certified breathwork facilitator and engage in an integration session (30 minute) with a licensed psychologist. Participants will be invited to engage in two, optional, virtual follow up breathwork sessions (40 minute practice each) during weeks 2... Read More
The goal of this single-site, single-arm pilot study is to examine the impact of breathwork training for posttraumatic stress symptoms in an adult veteran population. Participants will complete a single, in-person breathwork session (2 hours) led by a certified breathwork facilitator and engage in an integration session (30 minute) with a licensed psychologist. Participants will be invited to engage in two, optional, virtual follow up breathwork sessions (40 minute practice each) during weeks 2 and 3 following the in-person breathwork session. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Diamond Rose Sanctuary, Branford, Connecticut
Diamond Rose Sanctuary, Branford, Connecticut
Conditions: PTSD
Paid Clinical Trials in Connecticut
Paid clinical trials offer volunteers a unique chance to contribute to medical progress while reaping valuable rewards – both monetary and non-monetary benefits. Those who participate can receive fair compensation that can help cover expenses or invest in their future.
With CT paid clinical trials, people get access to new treatments that have yet to hit the market. They provide valuable data for innovation. This is the kind of innovation that can take medical knowledge to new heights.
Clinical Trials For Health Volunteers in Connecticut
Every volunteer in a clinical trial is a catalyst for change. With health volunteers, such as yourself, research teams in Connecticut can test new medications, therapies, and other factors that can have a positive impact on healthcare.
Browse the list below to find trials that can suit your needs.
CBD-Microglia PET Study
Recruiting
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/15/2025
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Connecticut Mental Health Center, New Haven, Connecticut
Conditions: CBD, Healthy
Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study
Recruiting
The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.
The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls. Read Less
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
10/29/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Cocaine Use Disorder, Healthy Controls
SV2A Density Cannabis Use Disorder
Recruiting
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after... Read More
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence. Finally, the relationship between hippocampal \[11C\]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Yale University School of Medicine, New Haven, Connecticut
Conditions: Cannabis Use Disorder, Healthy
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Recruiting
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.... Read More
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy. To evaluate associations between PET imaging radiotracers \[11C\]UCB-J, a ligand for presynaptic vesicle protein 2A (SV2A), a vesicle membrane protein expressed in synapses, and PET \[11C\]PBR28 a measure of microglia function in the brain, the Yale PET center has developed an advanced approach of combining multiple distinct ligands in coordinated same-day PET imaging. Additionally, the study will evaluate the associations of this novel synaptic density marker with well-established clinical measures of neurocognitive performance and laboratory measures of blood and cerebrospinal fluid (CSF). Read Less
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/05/2024
Locations: Yale School of Medicne, Neuro ID Research Program, New Haven, Connecticut
Yale School of Medicne, Neuro ID Research Program, New Haven, Connecticut
Conditions: HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
OMAR Opioid Use Disorder
Recruiting
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Conditions: Healthy Control, Opioid Use Disorder
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
Recruiting
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects. Read Less
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/24/2025
Locations: Clinical Site 1, New Haven, Connecticut
Clinical Site 1, New Haven, Connecticut
Conditions: Healthy Volunteers
Psychedelic Virtual Reality
Recruiting
The purpose of this study is to evaluate a novel VRP.
The purpose of this study is to evaluate a novel VRP. Read Less
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/22/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Yale University School of Medicine, New Haven, Connecticut
Conditions: Psychedelic Experiences, Virtual Reality, Healthy Volunteer
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
Recruiting
The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:
1. Do serotonergic psychedelics cause the brain to rely on new information more than previ... Read More
The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:
1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use?
2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs?
3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect?
4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics?
Researchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics.
Participants will have the opportunity to do some combination of the following:
1. Online computer assessments consisting of games and questionnaires that probe how participants think.
2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered.
3. A magnetic resonance imaging (MRI) scan.
4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/12/2024
Locations: Connecticut Mental Health Center, Hamden, Connecticut +1 locations
Connecticut Mental Health Center, Hamden, Connecticut
West Haven VA Medical Center, West Haven, Connecticut
Conditions: OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults
Recruiting
The purpose of this study is to learn about how different amounts of study medicine called PF-06414300 acts and is changed and eliminated from the body of healthy adult participants. The amount of PF-06414300 in blood after the medicine is taken by mouth will also be measured.
The study is seeking for participants who:
* Are male or female of 18 to 65 years of age.
* Are in good health condition.
* Have body mass index of 16 to 32 kilograms per squared meters; and a total body weight of more t... Read More
The purpose of this study is to learn about how different amounts of study medicine called PF-06414300 acts and is changed and eliminated from the body of healthy adult participants. The amount of PF-06414300 in blood after the medicine is taken by mouth will also be measured.
The study is seeking for participants who:
* Are male or female of 18 to 65 years of age.
* Are in good health condition.
* Have body mass index of 16 to 32 kilograms per squared meters; and a total body weight of more than 50 kilograms (110 pounds).
All participants in this study will receive either PF-06414300 or placebo (dummy pill) by chance. The study will have 2 parts; in the first part of the study (Part A), each participant will receive a total of 4 doses of PF-06414300 or placebo with at least 10 to 14 days between each dose. After each dose, participants will stay in study clinic for 4 to 5 days.
In the second part of the study (Part B), each participant will receive a total of 10 doses of PF-06414300 or placebo and participants will stay in study clinic for 14 days.
An optional Japanese cohort may be done later. The planned duration of participation from screening to follow up in Part A and B of this study is up to 12 to 14 weeks and 10 to 12 weeks, respectively.
Participants will also have their blood collected by the study doctors several times. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/23/2024
Locations: Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Conditions: Healthy Participants
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
Recruiting
The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.
The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/20/2025
Locations: Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Conditions: Healthy
Medical Discoveries and Innovation in Connecticut
Connecticut has many dedicated healthcare professionals and research institutions that have made notable contributions to health and medicine. Here is a list of some of the discoveries the state is famous for.
- Discovery of Lyme Disease: In the 1970s, Dr. Allen Steere and his mentor Stephen Malawista discovered and named Lyme disease. At the time, Dr. Steere was working at Yale University in Connecticut. Since then, he has published about 300 scholarly articles on the infection.
- Advancements in Cardiovascular Surgery: Dr. William W. L. Glenn was a renowned heart surgeon. He invented a technique to treat congenital heart disease. He also participated in creating the early version of an artificial heart. From 1948 to 1975, he was the chief of heart surgery at Yale University.
- The First Artificial Heart: Dr. Robert K. Jarvik is a Connecticut-based physician who invented the first permanently implantable artificial heart. This groundbreaking medical device paved the way for future advancements in heart transplantation and cardiovascular care.
Why Connecticut Is A Great Place For Clinical Research
The Connecticut population is diverse, making it a great choice for clinical research. Data shows that 64.6% of its residents are White, 17.7% are Hispanic, 10.6% are Black, 4.9% are Asian, and 1.9% are Multiracial.